Antigen Express.

Antigen Express awarded Therapeutic Discovery Project grants for cancer vaccine development Generex Biotechnology Corporation announced today that it is wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc les artikkelen . and the Division of Health insurance and Human Providers pursuant to the Patient Protection and Affordable Treatment Work of 2010. The Antigen Express Therapeutic Discovery Tasks are entitled: Ii-Key Her-2/neu Peptide Vaccine, for the treatment of breast cancerIi-Key Her-2/neu Peptide Vaccine, for the treating prostate cancerRelated StoriesCrucial modification in single DNA bottom predisposes children to aggressive form of cancerFDA grants accelerated authorization for Tagrisso to treat patients with advanced NSCLCCornell biomedical engineers develop 'super natural killer cells' to destroy tumor cells in lymph nodesThe proprietary vaccine getting developed by Antigen Express can be an off-the-shelf product made to reduce the threat of relapse in tumor patients.S.